Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19797339 | 0.89 | RET (1.00) | RET | |
| SCHEMBL19795805 | 0.89 | RET (0.84) | RET | |
| SCHEMBL19795819 | 0.85 | RET (0.86) | RET | |
| SCHEMBL19796299 | 0.85 | RET (0.73) | RET | |
| SCHEMBL19796173 | 0.85 | RET (0.73) | RET | |
| SCHEMBL19795809 | 0.83 | RET (1.00) | RET | |
| SCHEMBL19796198 | 0.82 | RET (0.77) | RET | |
| Lithium Ion SCHEMBL30990489 | 0.81 | RET (0.68) | RET | |
| SCHEMBL19797338 | 0.81 | RET (1.00) | RET | |
| SCHEMBL19796087 | 0.80 | RET (1.00) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227329-B2 | Compounds useful for treating disorders related to RET | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180022732-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION | 2018-01-25 | — | — | US | disclosed |
| US-20180022732-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION | 2018-01-25 | — | — | US | disclosed |
| WO-2018017983-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227329-B2 | Compounds useful for treating disorders related to RET | RET, EYA2, HRAS | RET 1/4885 |
| US-20180022732-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | RET, EYA2, HRAS | RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.